Dynavax Technologies (NASDAQ:DVAX - Get Free Report) is set to issue its quarterly earnings data after the market closes on Thursday, November 7th. Analysts expect the company to announce earnings of $0.10 per share for the quarter. Individual interested in registering for the company's earnings conference call can do so using this link.
Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last issued its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported $0.08 EPS for the quarter, beating analysts' consensus estimates of $0.06 by $0.02. The firm had revenue of $73.80 million for the quarter, compared to analysts' expectations of $76.92 million. Dynavax Technologies had a net margin of 6.88% and a return on equity of 2.76%. During the same period in the prior year, the company earned $0.03 EPS. On average, analysts expect Dynavax Technologies to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Dynavax Technologies Price Performance
DVAX traded down $0.21 during midday trading on Thursday, reaching $11.85. 1,674,603 shares of the company's stock were exchanged, compared to its average volume of 2,096,373. The business's 50-day moving average price is $11.05 and its 200 day moving average price is $11.22. The stock has a market capitalization of $1.55 billion, a PE ratio of 107.73 and a beta of 1.37. Dynavax Technologies has a 1-year low of $9.74 and a 1-year high of $15.15. The company has a debt-to-equity ratio of 0.35, a current ratio of 14.18 and a quick ratio of 13.18.
Wall Street Analyst Weigh In
Several equities analysts have weighed in on DVAX shares. The Goldman Sachs Group dropped their price target on Dynavax Technologies from $20.00 to $15.00 and set a "neutral" rating for the company in a research report on Thursday, August 8th. HC Wainwright restated a "buy" rating and issued a $29.00 target price on shares of Dynavax Technologies in a report on Tuesday, October 15th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $23.67.
Read Our Latest Research Report on Dynavax Technologies
Dynavax Technologies Company Profile
(
Get Free Report)
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.
Featured Articles
Before you consider Dynavax Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dynavax Technologies wasn't on the list.
While Dynavax Technologies currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
